



Calithera Biosciences Announces Five Data Presentations at the American Association for Cancer Research Annual Meeting 2015

March 18, 2015

SOUTH SAN FRANCISCO, Calif., March 18, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA) a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced the upcoming presentation of five preclinical abstracts, highlighting the potential of CB-839, the Company's novel, orally bioavailable glutaminase inhibitor, at the American Association for Cancer Research, taking place April 18-22, 2015 in Philadelphia, Pennsylvania. Details for the two oral presentations and three poster presentations are as follows:

Oral Presentations:

Evaluation of the glutaminase inhibitor CB-839 in non-small cell lung cancer

Abstract #4710

Presenter: Lindsey Boroughs, Laboratory of Ralph Debaradinis, UT Southwestern

Minisymposium: Metabolism and Cancer 3

Tuesday, April 21, 2015 at 3:35pm-3:50pm EDT

Pennsylvania Convention Center, Room 201

CB-839, a selective glutaminase inhibitor, synergizes with signal transduction pathway inhibitors to enhance anti-tumor activity

Abstract #4711

Presenter: Frank Parlati, Calithera Biosciences

Minisymposium: Metabolism and Cancer 3

Tuesday, April 21, 2015 at 3:50pm-4:05pm EDT

Pennsylvania Convention Center, Room 201

Poster Presentations:

Glutaminase inhibitors suppress pyrimidine synthesis and promote DNA replication stress in VHL-deficient human renal cancer cells

Abstract #1123

Presenter: Arimichi Okazaki, Laboratory of Othon Iliopoulos, Massachusetts General Hospital

Poster Section 6, Board 1

Monday, April 20, 2015 at 8:00am-12:00pm EDT

CB839, an orally bioavailable glutaminase inhibitor, shows potent antitumor activity in vitro against models of soft tissue sarcoma and chondrosarcoma

Abstract #4450

Presenter: Tahir Sheikh, Laboratory of Gary Schwartz, Columbia University

Poster Section 30, Board 7

Tuesday, April 21, 2015 at 1:00pm-5:00pm EDT

A new anticancer strategy based on inhibiting mitochondrial proline dehydrogenase (PRODH) and exploiting synthetic lethal interactions with p53 restoration and/or glutaminase (GLS1) inhibition

Abstract #5402

Presenter: Gary Scott, Laboratory of Christopher Benz, Buck Institute

Poster Section 30, Board 14

Wednesday, April 22, 2015 at 8:00am-12:00pm EDT

The meeting abstracts can be viewed online through the AACR website at www.aacr.org.

About Calithera Biosciences

Calithera Biosciences is a clinical-stage company focused on discovering and developing novel small molecule drugs directed against tumor

metabolism and tumor immunology. Calithera's lead clinical candidate, CB-839, is a first-in-class inhibitor of glutaminase, a critical enzyme in tumor metabolism, and is currently being tested in patients with solid and hematological cancers. Calithera Biosciences is headquartered in South San Francisco. For more information about Calithera Biosciences, please visit www.calithera.com.

CONTACT: Jennifer McNealey
ir@Calithera.com
650-870-1071

[Calithera Biosciences](#)

Calithera Biosciences, Inc.